An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement

Andrew J. Sunderland, Raphael E. Steiner, Musa Al Zahrani, Chelsea C. Pinnix, Bouthaina Shbib Dabaja, Jillian R. Gunther, Loretta J. Nastoupil, Mats Jerkeman, David Joske, Gavin Cull, Tarec El-Galaly, Diego Villa, Chan Yoon Cheah

Research output: Contribution to journalArticle

Abstract

Marginal zone lymphoma of the central nervous system (CNS MZL) is rare. The clinical features, treatment, and prognosis are not well characterized. We performed a multicenter retrospective study of CNS MZL. Twenty-six patients were identified: half with primary and half with secondary CNS involvement. The median age was 59 years (range 26-78), 62% female and 79% with ECOG performance status ≤ 1. The most common disease site was the dura (50%). Treatment was determined by the treating physician and varied substantially. After a median follow up of 1.9 years, the estimated 2-year progression-free (PFS) and overall survival (OS) rates were 59% and 80%, respectively. Secondary CNS MZL was associated with 2-year OS of 58%. CNS MZL is rare, but relative to other forms of CNS lymphoma, outcomes appear favorable, particularly among the subset of patients with dural presentation and primary CNS presentation.

Original languageEnglish (US)
Pages (from-to)663-670
Number of pages8
JournalCancer medicine
Volume9
Issue number2
DOIs
StatePublished - Jan 1 2020

Fingerprint

Lymphoma
Central Nervous System
Multicenter Studies
Survival Rate
Retrospective Studies
Physicians
Survival
Therapeutics

Keywords

  • CNS lymphoma
  • marginal zone lymphoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. / Sunderland, Andrew J.; Steiner, Raphael E.; Al Zahrani, Musa; Pinnix, Chelsea C.; Dabaja, Bouthaina Shbib; Gunther, Jillian R.; Nastoupil, Loretta J.; Jerkeman, Mats; Joske, David; Cull, Gavin; El-Galaly, Tarec; Villa, Diego; Cheah, Chan Yoon.

In: Cancer medicine, Vol. 9, No. 2, 01.01.2020, p. 663-670.

Research output: Contribution to journalArticle

Sunderland, AJ, Steiner, RE, Al Zahrani, M, Pinnix, CC, Dabaja, BS, Gunther, JR, Nastoupil, LJ, Jerkeman, M, Joske, D, Cull, G, El-Galaly, T, Villa, D & Cheah, CY 2020, 'An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement', Cancer medicine, vol. 9, no. 2, pp. 663-670. https://doi.org/10.1002/cam4.2732
Sunderland, Andrew J. ; Steiner, Raphael E. ; Al Zahrani, Musa ; Pinnix, Chelsea C. ; Dabaja, Bouthaina Shbib ; Gunther, Jillian R. ; Nastoupil, Loretta J. ; Jerkeman, Mats ; Joske, David ; Cull, Gavin ; El-Galaly, Tarec ; Villa, Diego ; Cheah, Chan Yoon. / An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. In: Cancer medicine. 2020 ; Vol. 9, No. 2. pp. 663-670.
@article{34f81d7c8b054c1b911c69ca67e30c52,
title = "An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement",
abstract = "Marginal zone lymphoma of the central nervous system (CNS MZL) is rare. The clinical features, treatment, and prognosis are not well characterized. We performed a multicenter retrospective study of CNS MZL. Twenty-six patients were identified: half with primary and half with secondary CNS involvement. The median age was 59 years (range 26-78), 62{\%} female and 79{\%} with ECOG performance status ≤ 1. The most common disease site was the dura (50{\%}). Treatment was determined by the treating physician and varied substantially. After a median follow up of 1.9 years, the estimated 2-year progression-free (PFS) and overall survival (OS) rates were 59{\%} and 80{\%}, respectively. Secondary CNS MZL was associated with 2-year OS of 58{\%}. CNS MZL is rare, but relative to other forms of CNS lymphoma, outcomes appear favorable, particularly among the subset of patients with dural presentation and primary CNS presentation.",
keywords = "CNS lymphoma, marginal zone lymphoma",
author = "Sunderland, {Andrew J.} and Steiner, {Raphael E.} and {Al Zahrani}, Musa and Pinnix, {Chelsea C.} and Dabaja, {Bouthaina Shbib} and Gunther, {Jillian R.} and Nastoupil, {Loretta J.} and Mats Jerkeman and David Joske and Gavin Cull and Tarec El-Galaly and Diego Villa and Cheah, {Chan Yoon}",
year = "2020",
month = "1",
day = "1",
doi = "10.1002/cam4.2732",
language = "English (US)",
volume = "9",
pages = "663--670",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement

AU - Sunderland, Andrew J.

AU - Steiner, Raphael E.

AU - Al Zahrani, Musa

AU - Pinnix, Chelsea C.

AU - Dabaja, Bouthaina Shbib

AU - Gunther, Jillian R.

AU - Nastoupil, Loretta J.

AU - Jerkeman, Mats

AU - Joske, David

AU - Cull, Gavin

AU - El-Galaly, Tarec

AU - Villa, Diego

AU - Cheah, Chan Yoon

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Marginal zone lymphoma of the central nervous system (CNS MZL) is rare. The clinical features, treatment, and prognosis are not well characterized. We performed a multicenter retrospective study of CNS MZL. Twenty-six patients were identified: half with primary and half with secondary CNS involvement. The median age was 59 years (range 26-78), 62% female and 79% with ECOG performance status ≤ 1. The most common disease site was the dura (50%). Treatment was determined by the treating physician and varied substantially. After a median follow up of 1.9 years, the estimated 2-year progression-free (PFS) and overall survival (OS) rates were 59% and 80%, respectively. Secondary CNS MZL was associated with 2-year OS of 58%. CNS MZL is rare, but relative to other forms of CNS lymphoma, outcomes appear favorable, particularly among the subset of patients with dural presentation and primary CNS presentation.

AB - Marginal zone lymphoma of the central nervous system (CNS MZL) is rare. The clinical features, treatment, and prognosis are not well characterized. We performed a multicenter retrospective study of CNS MZL. Twenty-six patients were identified: half with primary and half with secondary CNS involvement. The median age was 59 years (range 26-78), 62% female and 79% with ECOG performance status ≤ 1. The most common disease site was the dura (50%). Treatment was determined by the treating physician and varied substantially. After a median follow up of 1.9 years, the estimated 2-year progression-free (PFS) and overall survival (OS) rates were 59% and 80%, respectively. Secondary CNS MZL was associated with 2-year OS of 58%. CNS MZL is rare, but relative to other forms of CNS lymphoma, outcomes appear favorable, particularly among the subset of patients with dural presentation and primary CNS presentation.

KW - CNS lymphoma

KW - marginal zone lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85076264993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076264993&partnerID=8YFLogxK

U2 - 10.1002/cam4.2732

DO - 10.1002/cam4.2732

M3 - Article

C2 - 31808316

AN - SCOPUS:85076264993

VL - 9

SP - 663

EP - 670

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 2

ER -